The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia

Detalles Bibliográficos
Autores principales: Lim, Byungho, Yoo, Dabin, Chun, Younghwa, Go, Areum, Cho, Kyung-Jin, Choi, Daeun, Jung, Myoung Eun, Lee, Ha Young, Boohaker, Rebecca J., Lee, Jin Soo, Jung, DooYoung, Choi, Gildon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001641/
https://www.ncbi.nlm.nih.gov/pubmed/35410412
http://dx.doi.org/10.1038/s41408-022-00664-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001641/
https://www.ncbi.nlm.nih.gov/pubmed/35410412
http://dx.doi.org/10.1038/s41408-022-00664-y

Ejemplares similares